Vista Pharmaceuticals Ltd (VISTAPH) is currently trading at 5.89 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Vista Pharmaceuticals Limited formulates pharmaceutical products, primarily in therapeutic areas like gastrointestinal, pain management, and anti-infection drugs, targeting common ailments. The company was the first Indian firm to receive USFDA approval for producing both OTC and prescription drugs for the US market in 1994. Vista Pharmaceuticals has set up a 100% EOU to manufacture drug formulations with a significant annual capacity, showing its commitment to scaling operations. The company's Indian facility received USFDA approval in 2010 for producing ANDA products, reinforcing its quality compliance and operational standards. Vista Pharmaceuticals has an established marketing and distribution network in the United States, ensuring strong international presence and demand.

Over the past 52 weeks, Vista Pharmaceuticals Ltd has traded between a low of ₹5.50 and a high of ₹10.75. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Vista Pharmaceuticals Ltd has a market capitalization of approximately 35.70. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Vista Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -3.04 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 35.70 Cr, Vista Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Vista Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Vista Pharmaceuticals Ltd is -3.04. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Vista Pharmaceuticals reported a net loss of Rs 98.59 lakh for the quarter ended June 30, 2026, narrowing from a loss of Rs 129.04 lakh in Q1 FY25.

The company informed BSE that its board meeting is scheduled on 14 August 2026 to consider unaudited financial results for the quarter ended 30 June 2026.